| 产品描述: | PF-07054894 is an orally active and potent C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) antagonist that blocks CCR6-mediated chemotaxis with an IC50 value of 5.7 nM in vitro. PF-07054894 targets G protein-coupled receptor (GPCR). PF-07054894 can be used in research of inflammatory bowel disease. |
| 靶点: |
CCR6 |
| 体外研究: |
PF-07054894 (10 mg/kg,口服,每天两次,连续 6 天) 可以增加健康的食蟹猴中循环的 CCR6+ T 细胞[2][3]。 PF-07054894 (100 mg/kg,口服,每天一次或两次,持续 12 天) 在皮肤炎症小鼠模型中对白细胞介素-23 诱导的炎症有效[2]。 |
| 体内研究: |
PF-07054894 (1-3000 nM,1 小时) 以不可逆的方式抑制 CCL20/CCR6 介导的 T 细胞趋化。 |
| 参考文献: |
1. Gómez S, et, al. Desarrollo de anticuerpos terapéuticos contra el receptor CCR6 humano. 2. Li W, et al. A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6+ T Cells, and Ameliorates Interleukin-23-Induced Skin Inflammation. J Pharmacol Exp Ther. 2023 Jul;386(1):80-92. 3. Li W, et al. A novel CCR6 antagonist (PF-07054894) that distinguishes between homologous chemokine receptors, increases basal circulating CCR6+ T cells, and ameliorates interleukin-23-induced skin inflammation[J]. Journal of Pharmacology and Experimental Therapeutics, 2023. 4. Chinigo G M, et al. Early Process Development of PF-07054894, a Squaramide-Based Antagonist of C–C Chemokine Receptor Type 6 (CCR6)[J]. Organic Process Research & Development, 2024. |
| 保存条件: |
-80°C 6个月; -20°C 1个月,避光,氮气保存 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.143 ml |
10.717 ml |
21.435 ml |
| 5 mM |
0.429 ml |
2.143 ml |
4.287 ml |
| 10 mM |
0.214 ml |
1.072 ml |
2.143 ml |
| 50 mM |
0.043 ml |
0.214 ml |
0.429 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |